Inovio Pharmaceuticals (formerly known as Inovio Biomedical Corp) achieves unprecedented T-cell immune responses in human trial of DNA vaccine for cervical dysplasia and cancer caused by HPV.

Inovio Pharmaceuticals Inc (Inovio) has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18. This vaccine targets HPV E6 and E7 proteins and is delivered via in vivo electroporation. All dose groups developed significant antibody and T-cell immune responses; however, more notably, in the third and final dose group, five of six (83%) patients developed unprecedented T-cell responses not achieved by any other non-replicating vaccine platform in humans. Inovio is planning to start a Phase II clinical study in the 1Q 2011. …